
R^{607} is morpholine, piperidine, piperazine, pyrrolidine, diazepane, azetidine or O-C_{1-6} alkyl, wherein the piperidine, diazepane or azetidine groups can be optionally further substituted with OH or C_{1-6} alkyl.


36. The compound of claim 35, wherein R^{602} is methyl or isopropyl and R^{603} is methyl.

37. The compound of claim 35 or 36, wherein R^{604} is methyl and R^{605} is ethyl.

38. The compound of any of claims 35-37, wherein R^{606} is




or



.

39. The compound of any of claims 35-38, wherein R^{606} is



.

40. The compound of any of claims 35-39, wherein R^{607} is piperidine or diazepane, each of which is substituted with OH or C_{1-6} alkyl.

41. The compound of any of claims 35-39, wherein R^{607} is piperidine substituted with OH.

42. The compound of any of claims 35-40, wherein n_6 is 2.

43. A compound selected from those in Tables 1A and 1B, and pharmaceutically acceptable salts thereof.

44. A pharmaceutical composition comprising a compound of any of claims 1-43 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

45. Use of a compound of any of claims 1-43 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of lymphoma.

46. The use of claim 45, wherein the lymphoma is diffuse large B-cell lymphoma (DLBCL).

47. The use of claim 45, where in the lymphoma is non-Hodgkin's lymphoma (NHL).

48. The use of claim 45, wherein the lymphoma is follicular lymphoma.